BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, according to the majority of surveyed oncologists in the EU5 (France, Germany, Italy, Spain and the United Kingdom), although AstraZeneca’s Iressa is currently the most commonly used first-line treatment for epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer, the recent approval in this setting of Genentech/OSI Pharmaceuticals/Roche’s Tarceva will threaten Iressa’s market position. Together, these two targeted EGFR tyrosine kinase inhibitors will dominate first-line treatment of mutated EGFR non-small-cell lung cancer over chemotherapy, the longtime standard of care for non-small-cell lung cancer.
